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Background-—In patients with acute ischemic stroke and atrial ﬁbrillation, early anticoagulation prevents ischemic recurrence but
with the risk of hemorrhagic transformation (HT). The aims of this study were to evaluate in consecutive patients with acute stroke
and atrial ﬁbrillation (1) the incidence of early HT, (2) the time to initiation of anticoagulation in patients with HT, (3) the association
of HT with ischemic recurrences, and (4) the association of HT with clinical outcome at 90 days.
Methods and Results-—HT was diagnosed by a second brain computed tomographic scan performed 24 to 72 hours after
stroke onset. The incidence of ischemic recurrences as well as mortality or disability (modiﬁed Rankin Scale scores >2)
were evaluated at 90 days. Ischemic recurrences were the composite of ischemic stroke, transient ischemic attack, or
systemic embolism. Among the 2183 patients included in the study, 241 (11.0%) had HT. Patients with and without HT
initiated anticoagulant therapy after a mean 23.3 and 11.6 days, respectively, from index stroke. At 90 days, 4.6% (95%
conﬁdence interval, 2.3–8.0) of the patients with HT had ischemic recurrences compared with 4.9% (95% conﬁdence
interval, 4.0–6.0) of those without HT; 53.1% of patients with HT were deceased or disabled compared with 35.8% of those
without HT. On multivariable analysis, HT was associated with mortality or disability (odds ratio, 1.71; 95% conﬁdence
interval, 1.24–2.35).
Conclusions-—In patients with HT, anticoagulation was initiated about 12 days later than patients without HT. This delay was not
associated with increased detection of ischemic recurrence. HT was associated with increased mortality or disability. ( J Am Heart
Assoc. 2018;7:e010133. DOI: 10.1161/JAHA.118.010133.)
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P atients with acute ischemic stroke and nonvalvular atrialﬁbrillation (AF) are at a high risk of early recurrence.1,2 In
these patients, anticoagulant therapy (vitamin K antagonists
or non–vitamin K antagonists [NOACs]) reduces the risk of
recurrent ischemic stroke, but carries the risk of hemor-
rhagic transformation (HT). The possible intracerebral hem-
orrhagic complications in patients with acute stroke and AF
are (1) intracranial hemorrhage occurring during anticoag-
ulation therapy; (2) HT, ranging from hemorrhagic infarction
(HI) to parenchymal hemorrhage (PH) in the area of an
acutely infarcted brain after ischemic stroke; and
(3) worsening of HT due to anticoagulation therapy initiated
after the index stroke. In patients with acute stroke, early
HT was reported in about 9% within 5 to 7 days from the
index event. Of the observed HTs, 33% were PH and were
associated with an adverse 3-month outcome.3 In patients
with acute stroke and AF, the rate of HT is higher. On
neuroimaging performed 24 to 72 hours after stroke onset,
HT was observed in 13.0%: 8.8% HI and 4.2% PH.1 In
patients with acute stroke and AF, the presence of HT is
associated with a less favorable clinical outcome, and a
potential delay in the initiation of oral anticoagulant therapy
that could lead to an increase in the risk of early
recurrence.
The aims of this multicenter, prospective, international
study in consecutive patients with acute ischemic stroke and
AF were (1) to evaluate the incidence of early HT, (2) to
evaluate the time to initiation of oral anticoagulant therapy in
patients with HT, (3) to correlate the presence of HT with
ischemic recurrence, and (4) to assess the inﬂuence of HT on
clinical outcome at 90 days.
Methods
The authors declare that all supporting data are available
within the article.
We combined the databases of the RAF study and the RAF-
NOAC study,1,4 which were prospective observational studies
that were carried out between January 2012 and March 2014,
and between April 2014 and June 2016, respectively. Both
studies enrolled consecutive patients with acute ischemic
stroke and known or newly diagnosed AF without permanent
contraindications to anticoagulation. The study was approved
by the local institutional review boards, if required. Informed
consent was provided by study participants in countries
where this was required by law.
On admission, stroke severity was assessed in all patients
using the National Institutes of Health Stroke Scale (NIHSS);
noncontrast cerebral computed tomography (CT) or cerebral
magnetic resonance imaging (MRI) scan was performed to
exclude intracranial hemorrhage. Acute reperfusion therapies
and carotid revascularization procedures were delivered as
per standard local protocol, when appropriate. Standard
stroke unit care, monitoring, and treatment were provided
according to current international recommendations for acute
ischemic stroke. Attending physicians made decisions regard-
ing the type of anticoagulant to be prescribed for secondary
stroke prevention, as well as the day of initiation of
anticoagulant treatment. The RAF study included patients
treated with either vitamin K antagonists or NOACs, and the
RAF-NOAC study only patients who received NOACs.
A secondbrainCT scanorMRIwas scheduled tobeperformed
24 to 72 hours from stroke onset in all included patients.
HT was deﬁned as any degree of hyperdensity within the
area of low attenuation and was classiﬁed as either HI or PH.3
HI was deﬁned as small petechiae along the margins of the
infarct (HI-1) or as more conﬂuent petechiae within the
infarcted area but without space-occupying effect (HI-2). PH
was deﬁned as hematoma in <30% of the infarcted area with
some slight space-occupying effect (PH-1) or as dense
hematoma ≥30% of the infarcted area with substantial
space-occupying effect or as any hemorrhagic lesion outside
the infarcted area (PH-2). In cases of more than 1 hemor-
rhagic lesion on CT examination, the worst possible HT
category was assumed. For analysis purpose, we considered 2
groups of HT: HI-1 and HI-2 together (HI), and PH-1 and PH-2
together (PH). HT was considered symptomatic if it was not
seen on the admission CT and there was, subsequently, either
a suspicion of hemorrhage (eg, sudden headache) or a decline
in neurological status (an increase of ≥4 points in NIHSS).5
The site and size of the qualifying infarct were determined
based on standard templates and classiﬁed as (1) small, when
a lesion was <1.5 cm in the anterior or posterior circulations;
(2) medium, when a lesion was in a cortical superﬁcial branch
Clinical Perspective
What Is New?
• Hemorrhagic transformation (HT) patients with acute stroke
and atrial ﬁbrillation received anticoagulation about 12 days
later than patients without HT.
• This delay was not associated with a signiﬁcant increase in
ischemic recurrences (recurrent ischemic stroke, transient
ischemic attack, and systemic embolism).
• HT was associated with increased mortality and disability.
What Are the Clinical Implications?
• Early initiation of anticoagulation does not appear necessary
to prevent recurrent embolic events in HT patients.
• It may be beneﬁcial to avoid therapies that can cause early
HT.
• In addition to lesion size, reliable clinical and radiologic
predictors are needed to identify those patients at highest
risk for HT and worse outcomes.
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of the middle cerebral artery, in the middle cerebral artery
deep branch, in the internal border zone territories, in a
cortical superﬁcial branch of posterior cerebral artery, or in a
cortical superﬁcial branch of the anterior cerebral artery;
(3) large anterior, when a lesion involved the complete
territory of middle, posterior, or anterior cerebral artery; in 2
cortical superﬁcial branches of the middle cerebral artery; in a
cortical superﬁcial branch of the middle cerebral artery plus
the middle cerebral artery deep branch; or in more than 1
artery territory; (4) large posterior, when a lesion was >1.5 cm
in the brain stem or cerebellum.3
Risk Factors
Data on known stroke risk factors were collected as follows:
age, sex, history of hypertension (blood pressure >140/
90 mm Hg at least twice before acute stroke or already
under treatment with antihypertensive drugs), history of
diabetes mellitus (fasting glucose level >126 mg/dL prepran-
dial on 2 examinations, glucose level >200 mg/dL postpran-
dial, or HbA1c >6.5% or under antidiabetic treatment), current
cigarette smoking, past smoking (cessation <5 years prior),
hyperlipidemia (total cholesterol >200 mg/dL or triglyceride
>140 mg/dL or already under lipid-lowering therapy), history
of symptomatic ischemic heart disease (myocardial infarction,
history of angina, or previous diagnosis of multiple lesions on
thallium heart isotope scan or evidence of coronary disease
on coronary angiography), history of symptomatic peripheral
arterial disease (intermittent claudication of presumed
atherosclerotic origin; or ankle/arm systolic blood pressure
ratio <0.85 in either leg at rest, or history of intermittent
claudication with previous leg amputation, reconstructive
surgery, or angioplasty), alcohol abuse (>300 g per week),
obesity (body mass index >30 kg/m2), or previous stroke/
transient ischemic attack. White matter changes (leukoaraio-
sis deﬁned on the ﬁrst CT [or MR] examination as ill-deﬁned
and moderately hypodense [or hyperintensity on T2-weighted
MRI] areas >5 mm according to published criteria) were
investigated. Leukoaraiosis in the deep white matter was
dichotomized into absent versus present.6 Other baseline
variables obtained on admission for all patients included
fasting serum glucose, fasting serum cholesterol (total, high-
density lipoprotein, and low-density lipoprotein), platelet
count, international normalized ratios, activated partial
thromboplastin time, and systolic and diastolic blood
pressure.
The prescription of any antiplatelet or anticoagulant before
admission and the use of these agents on admission and
during the follow-up period was recorded.
The CHA2DS2VASc score (2 points for history of stroke or
age older than 75 years and 1 point each for congestive heart
failure, hypertension, diabetes mellitus, vascular disease, age
between 65 and 74 years, and female sex) was calculated
before and after the index event.
Evaluation of Outcome
Patients were followed up prospectively by face-to-face or
telephone interviews and review of medical charts. Three-
month ischemic recurrence was deﬁned as the composite of
recurrent ischemic cerebrovascular events (stroke or tran-
sient ischemic attack) and symptomatic systemic embolism.
Stroke was deﬁned as the sudden onset of a new focal
neurological deﬁcit of vascular origin in a site consistent with
the territory of a major cerebral artery and categorized as
ischemic or hemorrhagic. Transient ischemic attack was
deﬁned as a transient episode of neurological dysfunction
caused by focal brain ischemia without acute infarction.
Systemic embolism was deﬁned as an acute vascular
occlusion of an extremity or organ conﬁrmed by imaging,
surgery, or autopsy.
Symptomatic cerebral bleedings over 90-day follow-up
were also reported. Cerebral bleeding was considered symp-
tomatic if associated with a decline in neurological status (an
increase of ≥4 points in NIHSS score or leading to death).
Should an outcome event occur, patients were requested
to hand in the related full documentation in a face-to-face
visit.
Disability and mortality at 90 days were also assessed
using the modiﬁed Rankin Scale. Functional outcome was
deﬁned as either nondisabling (modiﬁed Rankin Scale score,
0–2) or disabling (modiﬁed Rankin Scale score, 3–5).
Statistical Analyses
Patient characteristics were summarized as mean and SD for
continuous variables and as absolute numbers and percent-
ages for categorical variables.
Differences in the baseline characteristics of patients with
or without HT were tested using the v2 test for nominal
variables or ANOVA for quantitative variables. In these
patients, univariate tests were used to compare both clinical
characteristics on admission and preexisting risk factors for
HT. A multivariable analysis was performed using logistic
regression to determine independent predictors of HT.
Differences in the characteristics of patients with or
without ischemic recurrence at 90 days were tested using the
v2 test for categorical variables or ANOVA for continuous
variables. In these patients, univariate tests were used to
compare both clinical characteristics on admission and
preexisting risk factors for ischemic events.
A multivariable analysis was performed using logistic
regression to determine independent predictors of ischemic
events. Furthermore, a multivariable analysis was performed
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using logistic regression to determine independent predictors
of mortality and disability at 90 days. Because it deals with
only one outcome at a time, a multivariable analysis was used
with logistic regression because the outcomes were binary.7
The independent variables included in the multivariable
models were selected from the univariate analysis with a
0.1 level as a screening criterion for selection of candidate
variables.
Survival function and empirical cumulative hazards func-
tion for ischemic recurrence were estimated via the Kaplan-
Meier estimator for patients with and without HT; the
differences between survival functions were tested using
the log-rank statistic (or Mantel-Haenszel test) that in the
case of large samples has an asymptotic v2 distribution.8
Patients were censored at the time of an outcome event or
death. A two-sided P<0.05 was considered signiﬁcant.
All statistical analyses were performed using the IBM SPSS
Statistics version 22.0 (IBM Corporation, Armonk, NY).
Results
A total of 2196 patients were enrolled in the study and 2183
were included in the analysis (13 patients were lost during
follow-up). On admission, 538 patients (24.5%) were on oral
anticoagulants. After the index acute stroke, 1218 patients
(55.8%) received NOACs, 567 (26.0%) vitamin K antagonists,
and 383 (17.3%) did not receive any anticoagulant therapy.
For the remaining 15 patients, no data were available
concerning the type of anticoagulant therapy. Patients treated
with NOACs initiated therapy after a mean of 13.2 days from
index stroke compared with a mean of 11.4 days for those
treated with vitamin K antagonists (P=0.06). More speciﬁcally,
166 patients treated with NOACs and 108 treated with
vitamin K antagonists initiated therapy within 24 hours from
acute index stroke.
Incidence and Predictors of HT
Among the 2183 patients included in the analysis, 241
(11.0%) had HT, of which 69 (3.1%) were PH; 13 of the 241
patients with HT were symptomatic (5.4%). All of these
symptomatic patients with HT had PH. Thirteen patients had
an HT that was observed on the ﬁrst neuroimaging examina-
tion at admission. The baseline characteristics of patients
with or without HT are summarized in Table 1. Patients with
HT were more likely to have congestive heart failure, higher
NIHSS score at presentation, treatment with acute reperfu-
sion therapies, and large lesions (P<0.05).
Table 1. Characteristics of the Patients With or Without HT
With HT (n=241) Without HT (n=1942) P Value
Age, y (mean SD) 75.69.9 76.49.8 0.19
Male sex 103 (42.7%) 900 (46.3%) 0.30
NIHSS on admission (median IQR) 11 (IQR, 12) 6 (IQR, 9) 0.0001
Diabetes mellitus 64 (26.6%) 424 (21.8%) 0.10
Hypertension 198 (82.0%) 1511 (77.8%) 0.07
Hyperlipidemia 83 (34.4%) 655 (33.7%) 0.82
AF paroxysmal 95 (39.4%) 829 (42.7%) 0.29
History stroke/TIA 52 (21.6%) 516 (26.6%) 0.19
Current smoker 29 (12.0%) 176 (9.1%) 0.16
Alcohol 20 (8.2%) 120 (6.1%) 0.21
History of congestive heart failure 54 (22.4%) 319 (16.4%) 0.02
History of myocardial infarction 37 (15.4%) 262 (13.5%) 0.43
Small lesion 23 (9.7%) 806 (41.5%) 0.0001
Large lesion 95 (39.4%) 305 (15.7%) 0.0001
Leukoaraiosis 110 (45.6%) 993 (51.1%) 0.09
Therapy with rtPA and/or IA 42 (17.4%) 238 (12.3%) 0.03
Bridging therapy with LMWH 40 (16.6%) 332 (17.1%) 0.92
Bridging therapy with antiplatelets 155 (64.3%) 1250 (64.4%) 0.90
AF indicates atrial ﬁbrillation; HT, hemorrhagic transformation; IA, intra-arterial procedure; IQR, interquartile range; LMWH, low-molecular-weight heparin; NIHSS, National Institutes of
Health Stroke Scale; rtPA, recombinant tissue plasminogen activator; TIA, transient ischemic attack.
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Of the 538 patients who were on oral anticoagulant
treatment on admission, 55 (10.2%; 95% conﬁdence interval
[CI], 7.8–13.1) had HT at second brain CT scan compared with
183 of the 1645 (11.1%; 95% CI, 9.6–13.7) of the patients
who were not on anticoagulant treatment (P=0.2).
The result of the multivariable analysis (Table 2) showed
that the presence of a large lesion and history of congestive
heart failure were signiﬁcantly associated with HT (odds ratio
[OR], 1.92; 95% CI, 1.37–2.70; P=0.0001; and OR, 1.49;
95% CI, 1.05–2.20; P=0.02, respectively). Tables 3 and 4
report the results of multivariable analyses for HI and PH
separately.
Time of Initiation of Oral Anticoagulants in
Patients With HT
Of the 241 with HT, 174 (72.2%) initiated oral anticoagulants:
63 (36.2%) with vitamin K antagonists and 111 (63.8%)
NOACs. Of the 1942 patients without HT, 1626 initiated oral
anticoagulants (83.7%), 491 (30.2%) with vitamin K antago-
nists, and 1135 (69.8%) NOACs.
Patients with HT initiated anticoagulant therapy after a
mean of 23.3 days (median, 17; interquartile range [IQR], 24)
from index stroke compared with a mean of 11.6 days
(median, 7; IQR, 10) for those without HT (P=0.0001). In
patients with HT, those with HI initiated anticoagulant therapy
after a mean of 21.9 days (median, 15; IQR, 19) and patients
with PH after a mean of 28.2 days (median, 26; IQR, 27)
(P=0.0001). In Figure 1, the timing of initiating oral antico-
agulant therapy in patients with and without HT is reported.
Sixty-seven of the 241 (27.8%) patients with HT never initiated
anticoagulant therapy compared with 316 of 1942 (16.3%) of
those without HT.
Nine of the 166 patients (5.4%) treated with NOACs and
one of the 108 patients (0.9%) treated with vitamin K
antagonists, who initiated therapy within 24 hours from acute
index stroke, had early HT.
Of the 10 patients treated with oral anticoagulants within
24 hours from index stroke and early HT, 2 had large lesions,
5 had medium lesions, and 3 had small lesions.
Regarding patients treated with acute reperfusion therapy,
patients treated with intravenous recombinant tissue plas-
minogen activator with or without intra-arterial thrombec-
tomy, initiated anticoagulant therapy after a mean of
13.6 days (median, 7; IQR, 11) from index stroke compared
with a mean of 12.3 days (median, 8; IQR, 10) for those not
treated with recombinant tissue plasminogen activator
(P=0.2).
Inﬂuence of HT on Outcome
Over the 90-day follow-up, 111 ischemic recurrences were
recorded in 107 patients (82 ischemic strokes, 18 transient
ischemic attacks and 11 systemic embolisms) (Table 5).
Eleven of the 241 patients (4.6%; 95% CI, 2.3–8.0) with HT
had an ischemic recurrence compared with 96 of the 1942
(4.9%; 95% CI, 4.0–6.0) without HT. The 90-day risk of
ischemic recurrence was 2.9% (35 of 1218) for patients
Table 3. Results of Multivariable Model: Predictive Factors
for HI
Variable OR 95% CI P Value
Large lesion 1.49 1.00–2.22 0.05
NIHSS at admission 1.00 0.97–1.03 0.9
Diabetes mellitus 1.06 0.73–1.56 0.7
Hypertension 1.35 0.87–2.10 0.2
CHF 1.44 0.97–2.14 0.07
Leukoaraiosis 0.90 0.60–1.10 0.1
Reperfusion therapy 0.90 0.50–1.19 0.2
CHF indicates congestive heart failure; CI, conﬁdence interval; HI, hemorrhagic
infarction; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.
Table 4. Results of Multivariable Model: Predictive Factors
for PH
Variable OR 95% CI P Value
Large lesion 3.16 1.76–5.67 0.0001
NIHSS at admission 0.99 0.95–1.04 0.8
Diabetes mellitus 1.58 0.90–2.73 0.1
Hypertension 1.20 0.60–2.39 0.6
CHF 1.68 0.94–3.02 0.08
Leukoaraiosis 0.89 0.53–1.47 0.7
Reperfusion therapy 1.33 0.77 to 2.31 0.3
CHF indicates congestive heart failure; CI, conﬁdence interval; NIHSS, National Institutes
of Health Stroke Scale; OR, odds ratio; PH, parenchymal hematoma.
Table 2. Results of Multivariable Model: Predictive Factors
for HT
Variable OR 95% CI P Value
Large lesion 1.92 1.37–2.70 0.0001
NIHSS at admission 1.00 0.98–1.03 0.8
Diabetes mellitus 1.13 0.81–1.57 0.4
Hypertension 1.33 0.91–1.95 0.1
CHF 1.49 1.05–2.10 0.02
Leukoaraiosis 0.90 0.70–1.10 0.1
Reperfusion therapy 0.90 0.60–1.14 0.3
CHF indicates congestive heart failure; CI, conﬁdence interval; HT, hemorrhagic
transformation; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.
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treated with NOACs, 6.7% (38 of 567) for those treated with a
vitamin-K antagonist, and 8.9% (34 of 383) for those not
receiving any antithrombotic treatment. On multivariable
analysis (Table 6), the presence of HT was not associated
with ischemic recurrence (OR, 0.50; 95% CI, 0.15–1.30;
P=0.1). Vitamin K antagonists were associated with ischemic
Figure 1. Timing of initiating oral anticoagulant therapy in patients with and without HT. HT indicates
hemorrhagic transformation.
Table 5. Characteristics of the Patients With or Without Ischemic Recurrence
With Recurrence (n=107) Without Recurrence (n=2076) P Value
Age, y (median IQR) 10 (IQR, 12) 6 (IQR, 9) 0.03
Male sex 47 (43.9%) 945 (45.5%) 0.69
NIHSS on admission (meanSD) 10.48.0 8.36.7 0.001
Diabetes mellitus 38 (35.5%) 443 (21.3%) 0.002
Hypertension 92 (86.0%) 1597 (76.9%) 0.07
Hyperlipidemia 37 (34.6%) 697 (33.6%) 0.91
AF paroxysmal 31 (29.0%) 886 (42.7%) 0.003
History stroke/TIA 35 (32.7%) 528 (25.4%) 0.11
Current smoker 8 (7.5%) 196 (9.4%) 0.61
Alcohol 9 (8.4%) 131 (6.3%) 0.41
History of congestive heart failure 29 (27.1%) 340 (16.4%) 0.008
History of myocardial infarction 17 (15.9%) 275 (13.2%) 0.46
Small lesion 31 (29.0%) 796 (38.3%) 0.05
Large lesion 27 (25.2%) 368 (17.7%) 0.07
Leukoaraiosis 61 (57.0%) 1013 (48.8%) 0.10
Pacemaker 13 (12.1%) 133 (6.4%) 0.03
CHA2DS2-VASc score >4 after index stroke 94 (87.9%) 1573 (75.8%) 0.03
AF indicates atrial ﬁbrillation; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TIA, transient ischemic attack.
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recurrence when compared with NOACs (OR, 2.89; 95% CI,
1.66–4.80; P=0.0001) as was CHA2DS2-VASc as a continuous
variable (OR, 1.24 for 1-point increase, 95% CI, 1.01–1.52;
P=0.04).
Kaplan-Meier survival curve (Figure 2) suggested that
patients with HT had an apparent nonsigniﬁcant earlier
ischemic recurrence compared with those without HT (P=0.5).
Mean latencies from the index stroke and ischemic recur-
rence were 36.2 days (32.4) in patients without HT
compared with 30.0 days (20.9) in patients with HT (hazard
ratio, 0.8; 95% CI, 0.4–1.6; P=0.6).
Over the 90-day follow-up, 55 symptomatic cerebral
bleedings were recorded (2.5%; 95% CI, 1.9–3.0), and 13 of
these were seen in the 241 patients with HT. Indeed, these 13
events were reported as symptomatic within 72 hours from
stroke onset. Seven additional patients of the 241 with HT
(2.8%; 95% CI, 1.4–5.8) had a second symptomatic cerebral
bleed during follow-up, compared with 35 of 1942 patients
(1.8%; 95% CI, 1.3–2.5) without HT. In patients with HT, 6 of 7
had the second symptomatic cerebral bleed after the initiation
of anticoagulant therapy. The mean time between the
initiation of anticoagulants and the second cerebral bleed
was 8.5 days.
At 90-day follow-up, 128 (53.1%) of the 241 patients
with HT were deceased or disabled (91 of 172 [52%] with
HI and 37 of 69 [54%] with PH) compared with 695 of the
1942 patients (35.8%) without HT, P=0.001. Figure 3 shows
the distribution of scores on the modiﬁed Rankin Scale at
3 months in patients with and without HT. On multivariable
analysis, all types of HT were associated with mortality or
disability at 90 days (HT [OR, 1.71; 95% CI, 1.24–2.35];
P=0.001; HI [OR, 1.75; 95% CI, 1.21–2.53]; P=0.003; PH
[OR, 1.79; 95% CI, 1.00–3.27]; P=0.05). Other study
variables associated with mortality and disability were age
(OR, 1.05 for 1-year increase, 95% CI, 1.03–1.06;
P=0.0001), diabetes mellitus (OR, 1.40; 95% CI, 1.10–
1.79; P=0.007), and NIHSS on admission (OR, 1.18 for 1-
point increase; 95% CI, 1.16–1.20; P=0.0001). Acute
reperfusion therapies were inversely associated with mor-
tality or disability (OR, 0.70; 95% CI, 0.51–0.96; P=0.027)
(Table 7).
Regarding the 67 patients with HT who were not
prescribed anticoagulant therapy, 6 (9.0%) had an ischemic
recurrence, compared with 28 of the 316 (8.9%) without HT
(OR, 0.98; 95% CI, 0.39–2.49; P=0.1). Overall, 55 of the 67
patients (82.1%) with HT were deceased or disabled at
90 days compared with 219 of the 316 patients (69.3%)
without HT (OR, 2.3; 95% CI, 1.4–3.96; P=0.03). In these
groups without anticoagulant therapy, 18 of the 67 patients
(26.9%) with HT were deceased at 90 days compared with 68
of the 316 patients (21.5%) without HT (OR, 1.33; 95% CI,
0.73–2.44; P=0.34).
Discussion
In our cohort of consecutive patients with acute ischemic stroke
and AF, we observed an 11% incidence of early HT. Patients with
HT initiated secondary prevention with oral anticoagulants on
average 12 days later than thosewithout HT, but this difference
was not associated with any detected increase in 90-day stroke
recurrence. HTwas shown to be associatedwithworse 3-month
functional outcome. This association did not appear to be
inﬂuenced by stroke recurrence due to a recorded delay in the
initiation of anticoagulation, but more likely due to a worsening
of stroke provoked by the presence of HT itself. About one third
of HT patients did not initiate anticoagulant therapy after the
hemorrhagic complication, compared with about 16% of those
Table 6. Results of Multivariable Model: Predictive Factors
for Ischemic Outcome Events (Stroke–TIA–Systemic
Embolism)
Variable OR 95% CI P Value
Vitamin K antagonist vs NOACs 2.89 1.66 to 4.80 0.0001
CHA2DS2-VASc (as a
continuous variable)
1.24 1.01 to 1.52 0.04
Paroxysmal AF 0.70 0.40 to 1.20 0.2
Small vs large lesion 0.66 0.37 to 1.19 0.2
NIHSS at admission 1.00 0.96 to 1.04 0.9
Pacemaker 1.89 0.80 to 4.31 0.2
Days from index stroke to
anticoagulation
1.00 0.99 to 1.01 0.3
Hemorrhagic transformation 0.50 0.15 to 1.30 0.1
AF indicates atrial ﬁbrillation; CI, conﬁdence interval; NIHSS, National Institutes of Health
Stroke Scale; NOACs, non–vitamin K antagonists; TIA, transient ischemic attack.
Figure 2. Cumulative risks (Kaplan-Meier survival curve) of
ischemic recurrence for patients with and without HT. HT
indicates hemorrhagic transformation.
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without HT. Patients with HT had more severe stroke and were
more likely to be deceased at 90 days, which plausibly limited
the subsequent number of ischemic recurrences that we could
detect. By 90 days, about 53% of HT patients were deceased or
disabled compared with about 36% of the patients without HT.
The Kaplan-Meier survival curve results suggest that patients
with HT perhaps had an earlier ischemic recurrence, even if not
signiﬁcant, compared with those without HT, despite the same
total number of ischemic outcome events at 90 days. If so, the
message for clinical practice might be to avoid early HT by
refraining from using anticoagulants in the very early phases of
acute stroke (24–48 hours), as this analysis observed that
about 5% of the patients who had initiated NOACs within
24 hours from index acute stroke suffered fromHT.Moreover, a
thorough evaluation for glycemia and an appropriate selection
of patients who need reperfusion therapy should be carried out.
Finally, a CT scan 2 to 3 days after the index acute stroke should
be performed before any anticoagulation strategy decision is
made. Reliable clinical and radiologic predictors are needed to
identify those patients at highest risk for HT. Our study supports
the hypothesis that the larger the lesion size, the greater its
predictive factor in HT and worse outcome.
Only 9% of the patients with HT were symptomatic. For this
reason, we suggest performing a second brain CT scan 2 to
3 days from stroke onset or before initiating anticoagulant
therapy to reduce the risk of worsening an asymptomatic HT.
This follow-up CT examination could also provide prognostic
indications for HT, even if asymptomatic, as HT generally
worsens outcome. In fact, it was reported that even “asymp-
tomatic” intracranial hemorrhage can be associated with
poorer long-term neurologic outcomes.9
Our study has several limitations. First, the reported
associations in our nonrandomized study were likely inﬂu-
enced by numerous potential confounders, even if adjusted
statistical models were used to reduce their effects. Second,
central adjudication of the outcome events and central
reading of vascular imaging for the measurement of ischemic
lesions were not performed. Speciﬁcally, the detection of
recurrent ischemic stroke might have differed in patients with
severe disability (especially for bedridden) compared with
those with minor disability. This is because, for bedridden
patients, the follow-up was more likely conducted by
Figure 3. Distribution of scores on the mRS at 3 months in patients with and without HT. HT indicates
hemorrhagic transformation; mRS, modiﬁed Rankin Score.
Table 7. Results of Multivariable Model: Predictive Factors
for Mortality or Disability
Variable OR 95% CI P Value
Age 1.05 1.03–1.06 0.0001
Sex, male 0.86 0.70–1.07 0.2
NIHSS at admission 1.18 1.16–1.20 0.0001
Diabetes mellitus 1.40 1.10–1.79 0.007
Hypertension 0.97 0.74–1.28 0.9
Hyperlipidemia 0.89 0.72–1.12 0.3
Reperfusion therapy 0.70 0.51–0.96 0.02
HT 1.71 1.24–2.35 0.001
HI 1.75 1.21–2.53 0.003
PH 1.79 1.00–3.27 0.05
CI indicates conﬁdence interval; HI, hemorrhagic infarction; HT, hemorrhagic
transformation; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; PH,
parenchymal hematoma.
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telephone rather than face-to-face. Third, the neuroimaging
follow-up examination could have differed among the centers,
even regarding type. In fact, at a few centers, brain MRI was
performed instead of CT scan with different sensitivity in
detecting hemorrhagic transformation. Finally, the study
might not have the power to detect a signiﬁcant difference
in ischemic recurrence in patients with and without HT.
The strengths of our study include the sample size and the
prospective design. Moreover, our ﬁndings reﬂect real-life
experiences and, in view of the presence of a single
inadequately powered randomized trial,10 may provide infor-
mation that could assist stroke physicians in the management
of patients with acute cerebral ischemia with AF.
In conclusion, early HT in patients with acute stroke and AF
was observed in 11% of our patients. The presence of HT
delayed the initiation of anticoagulant therapy. This delay was
not associated with any detected excess of ischemic recur-
rence. HT was independently associated with both mortality
and disability excess at 90 days.
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